OncoMatch/Clinical Trials/NCT04948619
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Is NCT04948619 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Vaccine for pediatric cancer.
Treatment: Vaccine — Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superior for regaining immunity against potentially serious infections in survivors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: cancer directed systemic therapy
History of any malignant diagnosis treated with at least one cycle of cancer directed systemic therapy
Cannot have received: observation, surgery, or radiotherapy alone
Malignant disease treated with observation, surgery, or radiotherapy alone
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Levine Cancer Institute · Charlotte, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04948619 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior observation, surgery, or radiotherapy alone disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify